On Tuesday, Johnson & Johnson mentioned it could droop photographs throughout the United States whereas federal well being companies investigated a small variety of rare blood clot instances, a transfer that some consultants concern will erode vaccine confidence.
The clotting concerns concerning the single-dose Johnson & Johnson vaccine intently mirror these over the AstraZeneca shot, which additionally makes use of adenovirus vector expertise to stimulate an immune response. It will not be recognized whether or not that expertise causes clotting.
Last month, drug regulators in Europe, the United Kingdom and Australia started inspecting the AstraZeneca vaccine after some recipients developed uncommon blood clots with low platelet counts, comparable to these of the Johnson & Johnson recipients.
UK regulators took a extra cautious strategy, saying wholesome adults beneath 30 needs to be supplied different vaccines. Officials described the transfer as a “course correction” that may not derail the nation’s fast inoculation program.
Australia, in the meantime, issued a blood clot warning on the AstraZeneca vaccine for folks beneath 50.
AstraZeneca has not but been licensed for emergency use within the US.
The Johnson & Johnson delay marks yet one more main setback for Europe’s vaccination efforts, which have been dogged by provide chain shortages, logistical points and concerns over the AstraZeneca vaccine. Despite the EMA steering, some European international locations have restricted AstraZeneca’s use for youthful folks, whereas different nations, together with Norway and Denmark, have suspended the shot.
The EU ordered 200 million doses of the Johnson & Johnson vaccine in 2021, and licensed its use on March 11. The UK has ordered 30 million doses of the Johnson & Johnson vaccine, however has not but licensed its use.
Revelations that each the Johnson & Johnson and AstraZeneca Covid-19 vaccines could have rare negative effects may even have huge implications for low- and middle-income international locations.
In February, South Africa’s well being minister introduced the nation had secured 9 million doses of the Johnson & Johnson vaccine and would supply its inventory of 1 million AstraZeneca doses to the African Union.